^
    BIOMARKER:

    MLL rearrangement

    i
    Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
    MLL rearrangement
    AML
    palbociclib
    Sensitive: C2 – Inclusion Criteria
    MLL rearrangement
    AML
    venetoclax
    Sensitive: C2 – Inclusion Criteria
    MLL rearrangement
    AML
    abemaciclib
    Sensitive: C3 – Early Trials
    MLL rearrangement
    ALL
    blinatumomab + inotuzumab ozogamicin
    Resistant: C3 – Early Trials
    MLL rearrangement
    ALL
    inotuzumab ozogamicin
    Resistant: C3 – Early Trials
    MLL rearrangement
    AML
    KO-539
    Sensitive: C3 – Early Trials
    MLL rearrangement
    B Acute Lymphoblastic Leukemia
    blinatumomab
    Resistant: C3 – Early Trials
    MLL rearrangement
    Childhood B Acute Lymphoblastic Leukemia
    MK-2206
    Sensitive: D – Preclinical
    MLL rearrangement
    B Acute Lymphoblastic Leukemia
    venetoclax
    Sensitive: D – Preclinical
    MLL rearrangement
    Leukemia
    JQ-1
    Sensitive: D – Preclinical